Shanghai BCI maker whose semi-invasive NEO implant (with Tsinghua) won the world's first commercial approval for an invasive-class BCI (NMPA, 2026).
Editorial profile — compiled by us from public sources.
Standings and milestones are always verified by us against primary sources, regardless of who manages the profile.
—
China's NMPA cleared Neuracle's coin-sized NEO implant (developed with Tsinghua) for commercial sale to restore hand function after spinal-cord injury — the first invasive-class BCI approved for market anywhere, ahead of Neuralink.
Neuracle's NMPA-approved NEO implant was surgically placed in a paying patient at a Shanghai hospital — a man who lost hand function in a car crash a decade ago — the first time a commercially approved BCI has been implanted anywhere, four months after clearance and ahead of Neuralink.
